Clinical Trial Update: Relative Bioavailability Study of Lipidil® Supra (Fenofibrate 160mg) Versus SYO-0805 (Fenofibrate 65mg) [Phase 1]

View source ↗

Summary

This document reports a Phase 1 relative bioavailability study comparing Lipidil Supra (fenofibrate 160 mg) to SYO-0805 (fenofibrate 65 mg). The study status is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipidemia

Drugs mentioned

• Lipidil Supra (Fenofibrate)
• SYO-0805 (Fenofibrate)

Snippet

Sponsor: Samyang Biopharmaceuticals Corporation | Conditions: Hyperlipidemia | Phase 1 | Status: COMPLETED